ArticleNature immunology2022
Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation.
Open access · hybridAbstract read
In one paragraph
Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers.
0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed
15.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 201 citations in OpenAlex.
- A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.Journal of neurology · 2023Trial
- Spatial multi‑omics identifies an SPP1+ macrophage‑driven anti‑apoptotic niche in osteoarthritis synovium via the SPP1‑CD44 axis.International journal of molecular medicine · 2026Article
- Article
- Chemokine levels in the murine brain from early postnatal development to aging.Brain, behavior, & immunity - health · 2026Article
- Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy.The Journal of experimental medicine · 2026Article
- Review
- Cell-free DNA methylation profiling reveals injury types and severities in swine rotational and contusional models of traumatic brain injury.Acta neuropathologica communications · 2026Article
- Intergenerational effects of the microbiota on neurodevelopment: mechanisms and therapeutic perspectives.Acta pharmacologica Sinica · 2026Review
- Harnessing Regulatory T Cells to Modulate Acute Brain Injury: From Mechanisms to Therapy.Molecular neurobiology · 2026Review
- Viral Infections and Neurodegenerative Diseases: Reinterpreting the Crosstalk Through a Dual-Role Lens.Current microbiology · 2026Review
- Single-cell RNA sequencing in stroke and traumatic brain injury: Current achievements, challenges and future perspectives on transcriptomic profiling.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Review
- Physical exercise promotes white matter repair after ischemic stroke.Neural regeneration research · 2026Article
- An Adnp frameshift variant disrupts Wnt signalling inducing chromatocytoskeletal defects and autism-related behaviour in male mice.EBioMedicine · 2026Article
- Regulatory T cells in stroke inflammation: Therapeutic perspectives.Neural regeneration research · 2026Article
- Psychosis as a multisystem disorder of aberrant aging.npj aging · 2026Review
- Article
- Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.Nature reviews. Drug discovery · 2026Review
- Neurodevelopmental comorbidities in juvenile systemic autoimmune and autoinflammatory diseases.Nature reviews. Rheumatology · 2026Review
- Astrocyte Functional Heterogeneity in Multiple Sclerosis.Journal of clinical neurology (Seoul, Korea) · 2026Review
- IL-3 Modulates Microglia Polarization and Attenuates Neuroinflammation in Traumatic Brain Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byCNS T2022
- Commented on by
Authors and funding
42 authors at 9 institutions in 5 countries.
Lidia Yshii *VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Emanuela Pasciuto *VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5391-9585
Pascal Bielefeld *Swammerdam Institute for Life Sciences, Faculty of Science, University of Amsterdam, Amsterdam, Netherlands.
Loriana MascaliVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Pierre LemaitreVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Marika MarinoVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6773-6176
James DooleyImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0003-3154-4708
Lubna KouserImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Stijn VerschorenVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6733-3481
Vasiliki LagouVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Hannelore KempsCardio & Organ Systems (COST), Biomedical Research Institute (BIOMED), Hasselt University, Diepenbeek, Belgium.ORCID http://orcid.org/0000-0001-9248-1697
Pascal GervoisCardio & Organ Systems (COST), Biomedical Research Institute (BIOMED), Hasselt University, Diepenbeek, Belgium.ORCID http://orcid.org/0000-0002-8320-1320
Antina de BoerVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Oliver T BurtonImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0003-3884-7373
Jérôme WahisVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Jens VerhaertVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Samar H K TareenImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Carlos P RocaImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Kailash SinghImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0002-6771-7757
Carly E WhyteImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0001-6556-6855
Axelle KerstensVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Zsuzsanna Callaerts-VeghKU Leuven, Faculty of Psychology, Laboratory of Biological Psychology, Leuven, Belgium.ORCID http://orcid.org/0000-0001-9091-2078
Suresh PoovathingalVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Teresa PrezzemoloVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Keimpe WierdaVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Amy DashwoodImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0002-4340-377X
Junhua XieVIB Center for Inflammation Research, Ghent, Belgium.
Elien Van WonterghemVIB Center for Inflammation Research, Ghent, Belgium.
Eline CreemersVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Meryem AloulouImmunology Programme, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Willy GsellKU Leuven, Department of Imaging and Pathology, Biomedical MRI, Leuven, Belgium.ORCID http://orcid.org/0000-0001-7334-6107
Oihane AbiegaSwammerdam Institute for Life Sciences, Faculty of Science, University of Amsterdam, Amsterdam, Netherlands.
Sebastian MunckVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Roosmarijn E VandenbrouckeVIB Center for Inflammation Research, Ghent, Belgium.ORCID http://orcid.org/0000-0002-8327-620X
Annelies BronckaersCardio & Organ Systems (COST), Biomedical Research Institute (BIOMED), Hasselt University, Diepenbeek, Belgium.
Robin LemmensVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Bart De StrooperVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Ludo Van Den BoschVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Uwe HimmelreichKU Leuven, Department of Imaging and Pathology, Biomedical MRI, Leuven, Belgium.
Carlos P FitzsimonsSwammerdam Institute for Life Sciences, Faculty of Science, University of Amsterdam, Amsterdam, Netherlands.
Matthew G Holt *VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium. mholt@i3S.up.pt.
Adrian Liston *VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium. al989@cam.ac.uk.ORCID http://orcid.org/0000-0002-6272-4085
VIB-KU Leuven Center for Brain & Disease Research · BEBabraham Institute · GBGhent University · BEHasselt University · BEKU Leuven · BEUniversity of Amsterdam · NLVIB-KU Leuven Center for Microbiology · BECentre National de la Recherche Scientifique · FRUK Dementia Research Institute · GB
Funding
Biotechnology and Biological Sciences Research Council BBS/E/B/000C0427Biotechnology and Biological Sciences Research Council BBS/E/B/000C0428
Abstract
The ability of immune-modulating biologics to prevent and reverse pathology has transformed recent clinical practice. Full utility in the neuroinflammation space, however, requires identification of both effective targets for local immune modulation and a delivery system capable of crossing the blood-brain barrier. The recent identification and characterization of a small population of regulatory T (T
Indexed as
AstrocytesBiological ProductsAnimalsBrainHumansInterleukin-2InterleukinsMiceNeuroinflammatory DiseasesT-Lymphocytes, RegulatoryBiological ProductsInterleukin-2Interleukins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.